Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…
Börse:
47,330$
2,67%
Echtzeit-Aktienkurs Agios Pharmaceuticals Inc.
Bid:
47,330$
Ask:
47,330$
Nachrichten zur Agios Pharmaceuticals Inc. Aktie
Agios Pharmaceuticals Inc (AGIO) Q2 2020 Earnings Call Transcript
AGIO earnings call for the period ending June 30, 2020....…
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AGIOS PHARMACEUTICALS, INC.: 10-Q Report
10-Q...…
Agios Pharmaceuticals, Inc. 2020 Q2 - Results - Earnings Call Presentation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do…
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million –...…
Agios Pharma CEO Jackie Fouse Looks Ahead After Lackluster Start
Agios Pharma CEO Jackie Fouse Looks Ahead After Lackluster Start...…
Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020
CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…
Agios Pharmaceuticals (AGIO) Presents At European Hematology Association Congress - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty
– Royalty Pharma Acquires Rights to Agios Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments –...…
Agios reports positive mitapivat data in sickle cell disease
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia
The FDA confers an orphan drug status on Agios (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock…
Thermo Fisher teams up with Agios on second companion diagnostic
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia
CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…
Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report?
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Moving Average Crossover Alert: Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable…
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year-
Is (AGIO) Outperforming Other Medical Stocks This Year?...…
Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
– TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant…
Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress
– Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation –...…
Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting
– Company to Present Additional Clinical Data Supporting Utility of TIBSOVO® in Cholangiocarcinoma and AML – – Company to Present…
Piper Sandler says buy the dip in Agios ahead of key data readouts
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat
Agios (AGIO) loss and revenues better estimates in Q1. The companys wholly owned leukemia drug Tibsovo sees a sequential rise…
Agios Pharmaceuticals Inc (AGIO) Q1 2020 Earnings Call Transcript
AGIO earnings call for the period ending March 31, 2020....…
Agios Pharmaceuticals, Inc.s (AGIO) CEO Jacqualyn Fouse on Q1 2020 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response
- First Quarter TIBSOVO® Net Revenue of $22.7 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105-115 Million -...…
Coronavirus Anchor Series: Agios With Strong Cash And 52-Week Low Price Has Good Potential
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb
- Celgene Declines to Exercise Opt-in Right for MAT2A Inhibitor AG-270 -...…
Agios IND for PKR Activator AG-946 Gets FDA Clearance
The FDA passes Agios (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin…
FDA clears Agios Pharmas IND for AG-946
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Is Agios Pharmaceuticals (AGIO) Down 28.7% Since Last Earnings Report-
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Agios Pharmaceuticals (AGIO) Presents At Cowen Health Care Conference - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios to Present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020
CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…
Agios (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat
Agios (AGIO) rides high on earnings and revenue beat in the fourth quarter of 2019....…
Agios Pharmaceuticals Inc (AGIO) Q4 2019 Earnings Call Transcript
AGIO earnings call for the period ending December 31, 2019....…
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q4 2019 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios Pharmaceuticals, Inc. 2019 Q4 - Results - Earnings Call Presentation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 10.11% and 13.97%, respectively, for the quarter ended December 2019. Do…
Agios Reports Fourth Quarter and Full Year 2019 Financial Results
- Fourth Quarter TIBSOVO® Net Revenue of $19.6M and $59.9M for Full Year 2019; Full Year 2020 U.S. TIBSOVO® Net…
Agios to Present at the Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020
CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…
SGKB Investment views: Immobilienfonds - Trotz hohen Agios einen Blick wert
Immobilienfonds sind keine Trading-Instrumente, sondern analog zu den Immobilien eine Langfristanlage....…
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy-
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Agios Pharmaceuticals (AGIO) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios CEO Jackie Fouse weighs in on the healthcare space
CNBC's Meg Tirrell with Agios CEO Jackie Fouse in an exclusive interview. With CNBC's Brian Sullivan and the Fast Money…
Agios: A Targeted Pharmaceutical Stairway To Value
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios sees Tibsovo sales as high as $115M this year
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Agios Announces "Agios 2025 Strategic Vision and Highlights 2020 Milestones
- In 2025, Company Expects to Have 4 Marketed Products in at Least 8 Indications, at Least 6 Molecules in…